Related Experiment Videos
Labetalol as monotherapy in hypertensive black patients
Insights
Labetalol effectively lowers blood pressure in Black patients with essential hypertension. This study found labetalol well-tolerated, significantly reducing diastolic blood pressure in most participants.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Clinical Hypertension
Background:
- Essential hypertension is a common condition requiring effective management.
- Black patients often exhibit unique responses to antihypertensive medications.
- Previous antihypertensive regimens may lose efficacy over time.
Purpose of the Study:
- To evaluate the antihypertensive efficacy of labetalol in adult Black patients with mild to moderate essential hypertension.
- To assess the tolerability and safety of labetalol in this patient population.
Main Methods:
- A washout period was implemented after patients discontinued previous antihypertensive medications.
- Labetalol was titrated up to 600 mg twice daily (BID) to achieve target blood pressure goals.
- Blood pressure and heart rate were monitored throughout the titration and maintenance periods.
Main Results:
- Labetalol significantly reduced standing systolic and diastolic blood pressure compared to baseline after washout (p < 0.01).
- Seventeen out of 18 patients achieved a diastolic blood pressure ≤ 90 mmHg.
- Labetalol therapy was well-tolerated, with minimal side effects reported.
Conclusions:
- Labetalol is an effective antihypertensive agent for Black patients with mild to moderate essential hypertension.
- The drug demonstrated good tolerability and a significant reduction in blood pressure.
- Labetalol offers a viable treatment option for this demographic previously controlled with other agents.
Abstract:
The antihypertensive effect of labetalol was evaluated in 18 adult black patients with mild to moderate essential hypertension previously controlled with a combination of a diuretic and a beta blocker. After a 4-week washout period, standing blood pressure had increased from 138 +/- 2.2/85 +/- 1.5 mmHg, (mean +/- SEM) to 154 +/- 1.9/100 +/- 0.6 mmHg. Labetalol was then titrated to a maximum of 600 mg BID to obtain a standing diastolic blood pressure of less than or equal to 90 mmHg and/or a decrease of greater than or equal to 10 mmHg from baseline (end of washout period). By the end of the labetalol titration period, standing blood pressure had decreased to 140 +/- 2.0/84 +/- 1.5 (p less than 0.01). Following a 2-week maintenance period, standing blood pressure was 136 +/- 1.6/80 +/- 1.5 mmHg (NS vs. titration). Labetalol therapy was well tolerated and reduced diastolic blood pressure to less than or equal to 90 mmHg in 17 of 18 patients, 13 of whom required dosages less than or equal to 300 mg BID. The average reduction in standing heart rate while on labetalol was 4 bpm (p less than 0.01). Side effects were limited to skin rash in one patient and possible mild urinary retention in another. These data indicate that labetalol is an effective antihypertensive for black patients with mild to moderate essential hypertension.